Skip to main content

Clinical Trials Using Therapeutic Autologous Lymphocytes

Review the clinical trials studying therapeutic autologous lymphocytes on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-200 of 212

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Genetically Engineered Cells (LMY-920) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Genetically Engineered Cells (Anti-CD19 CAR-T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies, The PRODIGY Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Genetically Engineered Cells (TmCD19-IL18 CAR T Cells) for the Treatment of Patients with Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Genetically Engineered Cells (DuoCAR20.19.22-D95) for the Treatment of Relapsed or Refractory B-Cell Cancers
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
A Personalized Vaccine (TTRNA-DCs & TTRNA-xALT) for the Treatment of Adult Patients with Recurrent/Progressive WHO Grade 2 or 3 Oligodendroglioma, ADAGiO Trial
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Autologous IC9-CAR19 T cells in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Tumor Infiltrating Lymphocytes for the Treatment of Children with High Risk Solid Tumors
Status: Active
Location: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Adoptive Cell Therapy (TTRNA-xALT), Dendritic Cell Vaccine (TTRNA-DC), and Hematopoietic Stem Cells in Combination with Pembrolizumab for the Treatment of Relapsed or Progressive Group 3 or 4 Non-SHH/Non-WNT Medulloblastoma, MATCHPOINT Trial
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
CD123-Directed Autologous or Donor Derived T-Cell Therapy for the Treatment of Relapsed or Refractory Acute Myelogenous Leukemia, CATCH-AML Study
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Memory-Like Natural Killer Cell Therapy with Interlekin-2, Nivolumab, and Relatlimab for the Treatment of Patients with Advanced or Metastatic Melanoma after Progression on Checkpoint Inhibitors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Status: Active
Location: See ClinicalTrials.gov
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Status: Active
Location: 2 locations
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
Status: Active
Location: See ClinicalTrials.gov
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Status: Active
Location: See ClinicalTrials.gov
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Autologous CAR19.20.22 Chimeric Antigen Receptor T Cells (CAR19.20.22 CART) for the Treatment of Recurrent or Refractory B-Cell Lymphomas
Status: Enrolling by Invitation
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Status: Enrolling by Invitation
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Genetically Modified T Cells (UF-KURE-BCMA CAR-T Cells) for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Infiltrating Lymphocytes and High-Dose Aldesleukin with or without Autologous Dendritic Cells in Treating Patients with Metastatic Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Dasatinib and Quercetin with CAR-T Therapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Status: Temporarily Closed to Accrual
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
E7777 to Enhance Regulatory T-Cell Depletion Prior to CAR-T for the Treatment of Relapsed/Refractory B-Cell Lymphomas
Status: Temporarily Closed to Accrual
Location: 2 locations